СЕНТРО ДЕ ИНХЕНЬЕРИЯ ХЕНЕТИКА И БИОТЕКНОЛОХИЯ (СИХБ) (CU);БИОРЕК С.А. (UY)
发明人:
УБЬЕТА ГОМЕС Раймундо (CU),АГИЛЕРА БАРРЕТО Ана (CU),МАРТИНЕС ДИАС Эдуардо (CU),ПАЕС МЕЙРЕЛЕС Роландо (CU),СЕРЕНО ГЕРРА Антонио (BE)
申请号：
RU2012139030/15
公开号：
RU2012139030A
申请日:
2011.02.10
申请国别(地区):
RU
年份:
2014
代理人:
摘要：
1. An orally administered pharmaceutical granule containing a core and enteric coating, wherein the core contains a pharmaceutically effective amount of epidermal growth factor and a sulfur-containing antioxidant selected from the group consisting of methionine and KSO. The granule according to claim 1, where the molar ratio between epidermal growth factor and antioxidant is from 1:20 to 1: 60.3. The granule according to claim 2, wherein the core further comprises a binding agent, an alkalizing agent, a glidant, a surfactant, or mixtures thereof. The granule according to claim 3, wherein the binder is hydroxypropyl methyl cellulose. The granule according to claim 3, wherein the alkalizing agent is disodium phosphate. The granule according to claim 3, where the glidant is talc. 7. The granule according to claim 3, wherein the surfactant is sodium lauryl sulfate. The granule according to claim 1, where the core contains: 60-80% by weight of the inert core； 0.05-1% by weight of the epidermal growth factor； 0.5-3% by weight of the antioxidant； 0.02-0.07% by weight the weight of the surfactant； 1.5-5% by weight of a binding agent； 0.02-0.07% by weight of an alkalizing agent； and 2-5% by weight of glidant. 9. The granule of claim 8, where the core contains: 69% by weight of an inert core； 0.10% by weight of epidermal growth factor； 1.3% by weight of methionine； 0.05% by weight of sodium lauryl sulfate； 2% by weight of hydroxypropyl methylcellulose； 0.05% by weight of disodium phosphate； and 4% by weight of talc. 10. The granule of claim 8, where the core contains: 69% by weight of an inert core； 0.10% by weight of epidermal growth factor； 2% by weight of KSO； 0.05% by weight of sodium lauryl sulfate； 2% by weight of hydroxypropyl methylcellulose； 0, 05% by weight of disodium phosphate； and 4% by weight of talc. 11. The granule according to claim 1, where the enteric coating1. Вводимая перорально фармацевтическая гранула, содержащая ядро и кишечнорастворимое покрытие, где
